mshivaiah, Author at Corcept Therapeutics - Page 2 of 2

About mshivaiah

This author has not written his bio yet.
But we are proud to say that mshivaiah contributed 19 entries already.

Entries by mshivaiah

Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer

Flint et al. • 2026 • Cancer Res

May 27, 2026

Co-secretion of Cortisol and Aldosterone in Individuals With Resistant Hypertension: Results From the MOMENTUM Trial

Sloan et al. • 2026 • AACE

April 24, 2026

Relacorilant Treatment Improves Glycemic Control Among Individuals With Cushing Syndrome (Endogenous Hypercortisolism) and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study

Silverstein et al. • 2026 • AACE

April 24, 2026

Real-World Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)

Coleman et al. • 2026 • SGO

April 13, 2026

Relacorilant Plus Nab-Paclitaxel Demonstrates a Progression-Free Survival Benefit in Ovarian Cancer Independent of Tumor Glucocorticoid Receptor (GR) Expression Levels

Lorusso et al. • 2026 • SGO

April 13, 2026

BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers

Lorusso et al. • 2026 • SGO

April 13, 2026

Final Overall Survival Results from the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)

Lorusso et al. • The Lancet • Olawaiye et al. • SGO • 2026

April 10, 2026

Prevalence and Clinical Impact of Hypercortisolism in Patients With Resistant Hypertension: Primary Results From the MOMENTUM Study

Bhatt et al. • 2026 • ACC.26

March 28, 2026

Efficacy and Safety of Relacorilant for the Treatment of Patients With Cushing’s Syndrome (GRACE): A Multicentre, Phase 3, Double-Blind, Placebo-Controlled, Randomised-Withdrawal Study

Pivonello • 2026 • The Lancet Diabetes & Endocrinology

February 20, 2026